Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBT: 2019-2024

Historic EBT for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to -$86.9 million.

  • Mirum Pharmaceuticals' EBT rose 119.03% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.8 million, marking a year-over-year increase of 58.33%. This contributed to the annual value of -$86.9 million for FY2024, which is 46.49% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported EBT of -$86.9 million as of FY2024, which was up 46.49% from -$162.4 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' EBT peaked at -$84.2 million during FY2021, and registered a low of -$162.4 million during FY2023.
  • Moreover, its 3-year median value for EBT was -$142.1 million (2022), whereas its average is -$130.5 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' EBT slumped by 96.32% in 2020 and then surged by 46.49% in 2024.
  • Yearly analysis of 5 years shows Mirum Pharmaceuticals' EBT stood at -$103.4 million in 2020, then increased by 18.53% to -$84.2 million in 2021, then crashed by 68.70% to -$142.1 million in 2022, then dropped by 14.33% to -$162.4 million in 2023, then skyrocketed by 46.49% to -$86.9 million in 2024.